

Department Winter Seminar Program 2024

* 質疑応答を含め 1 人 15 分を目安として下さい。

12 月 16 日 (月) Dec 16, Mon 9 : 00 ~ 16 : 50

I Cancer Immunotherapy 1

【 9 : 00~10 : 00 Chairperson/Y. Hirohashi 廣橋 良彦 】

1. What are we? Where are we going? Y. Hirohashi 廣橋 良彦
2. Therapeutic approaches utilizing the lactate-rich immunosuppressive tumor microenvironment to prostate cancer. T. Ogasawara 小笠原 卓音
3. (1) Relationship between hyperthermia and immunotherapy
(2) To explore the possible mechanism of complete remission after neoadjuvant therapy for breast cancer X. Liao 廖 雪洪
4. Immune responses in colorectal organoids and pancreatic cancers H. Miura 三浦 秀元

Break Time 【 10 : 00~10 : 10 】

II Cancer Immunotherapy2

【 10 : 10~11 : 10 Chairperson/T. Tsukahara 塚原 智英 】

5. Immunotherapy for sarcoma T. Tsukahara 塚原 智英
6. Identification of an antigen recognized by tumor-infiltrating lymphocyte in a patient with osteosarcoma T. Itabashi 板橋 尚秀
7. Development of novel immunotherapies through comprehensive cancer-testis antigen screening K. Murata 村田 憲治
8. Development of the T-cell engaging bispecific antibody targeting long noncoding RNA PVT1 H. Kato 加藤 大貴

Break Time 【 11 : 10~11 : 20 】

III Immune response to cancer cells

【 11 : 20～12 : 20 Chairperson／T. Kubo 久保 輝文 】

9. Physiology and Pathology of the Epithelial p63 in Immunity, Inflammation and Cancer
T. Kubo 久保 輝文
10. Striving to Improve Immunotherapy Outcomes in Lung Cancer
N. Shijubo 四十坊 直貴
11. Development of cancer prevention mRNA vaccine
K. Sasaki 佐々木 健太
12. Establishment of comprehensive detection methods for antigens recognised by TILs.
T. Nakayama 中山 貴敬

Lunch Time 【 12 : 20～13 : 20 】

IV Cancer immunotherapy 3

【 13 : 20～14 : 20 Chairperson／T. Kanaseki 金関 貴幸 】

13. Personalized Cancer Vaccine
T. Kanaseki. 金関 貴幸
14. NESSIE and beyond
S. Tokita 時田 芹奈
15. HLA class II neoantigen presentation in TLS within the TME
S. Matsumoto 松本 哲
16. Analysis of CD8 and CD4 T cell responses to oral cancer neoantigens.
T. Sato 佐藤 莊

Break Time 【 14 : 20～14 : 30 】

V Cancer Biology 1

【 14 : 30～15 : 15 Chairperson／K. Murata 村田 憲治 】

17. Analysis of antigen specificity of tumor infiltrating B lymphocytes in tertiary lymphoid structures positive cancer case
K. Hori 堀 寛太
18. Effect of low-temperature acclimation on T cell motility
T. Suzuki 鈴木 健史、R. Suzuki 鈴木 伶奈、M. Sugaya 管家 実佑、M. Hattori 服部 成裕
(Department of Biology, Sapporo Medical University)

19. Development of HLA-A2/Claspin peptide-specific artificial antibodies targeting platinum-resistant cancer cells. Y. Mizue 水江 由佳

Break Time 【 15 : 15～15 : 25 】

VI Cancer Biology 2

【 15 : 25～16 : 10 Chairperson／T. Torigoe 鳥越 俊彦 】

20. The Impact of odorant receptor OR7C1 on colorectal cancer stem cells. K. Hashimoto 橋本 薫
(Tokyo University of Agriculture and Technology)
21. Agonist screening for OR7C1 and functional comparative analysis between haplotypes
M. Okajima 岡島 雅樹
(Tokyo University of Agriculture and Technology)
22. Insights into odorant receptors expressed in the body. Y. Fukutani 福谷 洋介
(Tokyo University of Agriculture and Technology)

Break Time 【 16 : 10～16 : 20 】

VII Closing remarks

【 16 : 20～16 : 50 】

23. From therapeutic immunotherapy to prophylactic immunotherapy. The dreams come true.
T. Torigoe 鳥越 俊彦